Stock Movers Novo Dordisk Drops; Alibaba Soars; Biogen Rises
Nov 24, 2025
Novo Nordisk faced a setback as its pill version of Ozempic failed Alzheimer’s trials, leading to a significant drop in shares. This news unexpectedly benefited Biogen, causing its stock to rise. Meanwhile, Alibaba's Qwen app thrived post-relaunch, amassing over 10 million downloads, highlighting its competitive stance against AI giants like OpenAI. The discussion also touched on overall tech stock trends and market implications amid rising AI hype.
AI Snips
Chapters
Transcript
Episode notes
Oral Ozempic Fails Alzheimer’s Test
- Novo Nordisk's oral Ozempic failed to slow Alzheimer's progression in two high‑risk studies.
- The company will discontinue a planned one‑year extension and its shares plunged to the lowest since July 2021.
Competition And Trials Hurt Valuation
- Market worries about obesity competition and failed trials hammered Novo Nordisk's valuation this year.
- Paul Sweeney noted the stock is down roughly 50% and has erased about a trillion dollars of shareholder value.
Sector Ripples From Trial Results
- The failed Novo trials had cross‑stock effects across the sector.
- Biogen shares rose as analysts saw positive read‑throughs for other Alzheimer's treatments.